Immune-related encephalopathy at nivolumab effective treatment of lung adenocarcinoma. A case report
Автор: Yudin D.I., Laktionov K.K., Allahverdiev A.K., Sarantseva K.A., Tkachenko G.A., Musayev I.E., Breder V.V., Reutova E.V., Ardzinba M.S.
Журнал: Злокачественные опухоли @malignanttumors
Рубрика: Клинический случай
Статья в выпуске: 1 т.8, 2018 года.
Бесплатный доступ
Now the number of patients receiving immunotherapy with checkpoint inhibitors, including nivolumab, is growing all over the world. At the same time, there is a growing of immune-related adverse events in clinical practice, including rare ones. There is a case report of immune-related encephalopathy (grade 3) at patient with metastatic non-small cell lung cancer after complete response at nivolumab treatment.
Pd-1, анти-pd-1, nivolumab, non-small lung cancer, pd-l1, anti pd-1
Короткий адрес: https://sciup.org/140243826
IDR: 140243826 | DOI: 10.18027
